Guilin Sanjin Pharmaceutical Co Ltd (SHE:002275) — Market Cap & Net Worth
Market Cap & Net Worth: Guilin Sanjin Pharmaceutical Co Ltd (002275)
Guilin Sanjin Pharmaceutical Co Ltd (SHE:002275) has a market capitalization of $1.23 Billion (CN¥8.41 Billion) as of May 2, 2026. Listed on the SHE stock exchange, this China-based company holds position #8231 globally and #2091 in its home market, demonstrating a 1.42% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guilin Sanjin Pharmaceutical Co Ltd's stock price CN¥14.31 by its total outstanding shares 587568600 (587.57 Million). Analyse 002275 cash generation efficiency to see how efficiently the company converts income to cash.
Guilin Sanjin Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guilin Sanjin Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.46 Billion to $1.23 Billion (-0.37% CAGR).
Index Memberships
Guilin Sanjin Pharmaceutical Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$4.18 Trillion | 0.03% | #260 of 285 |
Weight: Guilin Sanjin Pharmaceutical Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Guilin Sanjin Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guilin Sanjin Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.59x
Guilin Sanjin Pharmaceutical Co Ltd's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.49x
Guilin Sanjin Pharmaceutical Co Ltd's market cap is 2.49 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.46 Billion | $1.39 Billion | $376.53 Million | 1.05x | 3.87x |
| 2016 | $1.18 Billion | $1.53 Billion | $393.66 Million | 0.77x | 3.00x |
| 2017 | $1.06 Billion | $1.62 Billion | $464.40 Million | 0.66x | 2.29x |
| 2018 | $861.59 Million | $1.58 Billion | $413.35 Million | 0.54x | 2.08x |
| 2019 | $906.03 Million | $1.64 Billion | $392.14 Million | 0.55x | 2.31x |
| 2020 | $1.05 Billion | $1.57 Billion | $277.02 Million | 0.67x | 3.78x |
| 2021 | $1.26 Billion | $1.74 Billion | $343.72 Million | 0.72x | 3.67x |
| 2022 | $1.05 Billion | $1.96 Billion | $329.53 Million | 0.54x | 3.20x |
| 2023 | $1.20 Billion | $2.17 Billion | $421.30 Million | 0.55x | 2.84x |
| 2024 | $1.30 Billion | $2.19 Billion | $521.53 Million | 0.59x | 2.49x |
Competitor Companies of 002275 by Market Capitalization
Companies near Guilin Sanjin Pharmaceutical Co Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to Guilin Sanjin Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Guilin Sanjin Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guilin Sanjin Pharmaceutical Co Ltd's market cap moved from $1.46 Billion to $ 1.23 Billion, with a yearly change of -0.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.23 Billion | +1.49% |
| 2025 | CN¥1.21 Billion | -6.56% |
| 2024 | CN¥1.30 Billion | +8.26% |
| 2023 | CN¥1.20 Billion | +13.74% |
| 2022 | CN¥1.05 Billion | -16.39% |
| 2021 | CN¥1.26 Billion | +20.30% |
| 2020 | CN¥1.05 Billion | +15.62% |
| 2019 | CN¥906.03 Million | +5.16% |
| 2018 | CN¥861.59 Million | -19.02% |
| 2017 | CN¥1.06 Billion | -9.79% |
| 2016 | CN¥1.18 Billion | -19.11% |
| 2015 | CN¥1.46 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Guilin Sanjin Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.23 Billion USD |
| MoneyControl | $1.23 Billion USD |
| MarketWatch | $1.23 Billion USD |
| marketcap.company | $1.23 Billion USD |
| Reuters | $1.23 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guilin Sanjin Pharmaceutical Co Ltd
Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more